Druggio Logo

Druggio

Rheumatoid arthritis

Rheumatoid arthritis (RA) is a common autoimmune disease that primarily manifests as chronic inflammatory arthropathy. Persistent synovitis leads to cartilage destruction, bone erosions and periarticular decalcification, subsequently resulting in impaired joint function. It is more common between the ages of 35 and 50 years, affecting three times more women than men. Susceptibility to RA is genetically determined with multiple genes contributing. Inheritance of HLA DRB1 alleles encoding a distinctive five-amino-acid sequence known as the "shared epitope" (SE) is the best characterized genetic risk factor. The mechanism by which the SE alleles contribute to the development of RA is not very clear. It has been postulated that the presence of these conserved sequences in the antigen-binding groove alters the way antigenic peptides are bound to and presented to T-cell lymphocytes. This, in turn, may trigger abnormal immune responses and lead to RA.

Drugs that treat Rheumatoid arthritis

Jyseleca

Approval date

2020/9/25

Rinvoq

Made by

AbbVie

Approval date

2020/1/23

Smyraf

Approval date

2019/3/26

Kevzara

Made by

Sanofi

Approval date

2017/9/27

Xeljanz

Made by

Pfizer

Approval date

2013/3/25

Cimzia

Made by

UCB

Approval date

2012/12/25

Enbrel

Made by

Pfizer

Approval date

2005/1/19

Arava

Made by

Sanofi

Approval date

2003/4/16